Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Department of Pediatrics, Bucheon, Republic of Korea
Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Department of Plastic and Reconstructive Surgery, Bucheon, Republic of Korea
J Clin Res Pediatr Endocrinol. 2021 Feb 26;13(1):104-108. doi: 10.4274/jcrpe.galenos.2020.2019.0223. Epub 2020 Apr 29.
Fibroma of tendon sheath (FTS) is an uncommon mass that arises from the tendon sheath of extremities. The tumor typically affects adults between ages 20 and 50 years with a predominance in males. To date, growth hormone (GH) treatment is safe for children with Turner syndrome without risk factors and is accepted worldwide. This article reports the case of a nine-year-old female patient with Turner syndrome and FTS during GH treatment. She had been treated with daily subcutaneous GH to improve growth failure with a mean dose of 0.28 mg/kg/week and the level of insulin-like growth factor-1 was within the normal range. During the follow-up period, she complained about a mass in her hand, subsequently diagnosed as FTS. This report illustrates the clinical impact of Turner syndrome and GH treatments on the occurrence of this tumor through literature reviews. Further studies are needed to highlight the association between FTS and GH treatment, especially in Turner syndrome.
腱鞘纤维瘤（FTS）是一种罕见的肿块，起源于四肢的腱鞘。这种肿瘤通常发生在 20 至 50 岁的成年人中，男性居多。迄今为止，生长激素（GH）治疗对无危险因素的特纳综合征儿童是安全的，并且在全球范围内得到认可。本文报告了一例在 GH 治疗期间患有特纳综合征和 FTS 的 9 岁女性患者。她每天接受皮下 GH 治疗以改善生长发育不良，平均剂量为 0.28mg/kg/周，胰岛素样生长因子-1 水平在正常范围内。在随访期间，她主诉手部有肿块，随后被诊断为 FTS。本报告通过文献复习说明了特纳综合征和 GH 治疗对这种肿瘤发生的临床影响。需要进一步的研究来强调 FTS 和 GH 治疗之间的关联，特别是在特纳综合征中。
